Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 14,963 |
|
|||||
| News | - | ||||||
| Day High | 14.49 | Low High |
|||||
| Day Low | 13.92 | ||||||
| Company Name | Etf Ticker Symbol | Market | Type |
|---|---|---|---|
| ETF Series Solutions Trust Range Cancer Therapeutics | CNCR | NASDAQ | Exchange Traded Fund |
| Price Change | Change Percent | Etf Price | Last Traded
|
|
|---|---|---|---|---|
| -0.25 | -1.74% | 14.11 | 17:16:11 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 14.30 | 13.92 | 14.49 | 14.11 | 14.36 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 143 | 14,963 | 14.21 | 212,620 | - | 9.22 - 18.00 |
| Last Trade Time | Type | Quantity | Etf Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 9 | 14.11 | USD |
ETF Series Solutions Trust Range Cancer Therapeutics Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 11.22M | 800.00k | - | 70k | -4.62M | -5.77 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News ETF Series Solutions Tru...
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
CNCR Historical
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 15.91 | 15.91 | 13.92 | 14.62 | 55,886 | -1.80 | -11.31% |
| 1 Month | 16.42 | 16.781 | 13.92 | 15.30 | 29,192 | -2.31 | -14.07% |
| 3 Months | 14.00 | 18.00 | 13.8371 | 16.25 | 40,693 | 0.11 | 0.79% |
| 6 Months | 10.12 | 18.00 | 9.22 | 15.77 | 21,530 | 3.99 | 39.43% |
| 1 Year | 12.55 | 18.00 | 9.22 | 15.24 | 13,549 | 1.56 | 12.43% |
| 3 Years | 29.11 | 32.99 | 9.22 | 17.43 | 8,905 | -15.00 | -51.53% |
| 5 Years | 19.84 | 35.818 | 9.22 | 20.83 | 10,004 | -5.73 | -28.88% |
| The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 25 pharmaceutical or biotechnology companies identified by the funds index provider, as having a high strategic focus on the development of drugs that harness the bodys own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified. |
